FDA clears Life Spine ’ s Pro-Link Ti cervical spacer
Life Spine said today that it won 510(k) clearance from the FDA for its Pro-Link Ti cervical spacer. The Huntley, Ill.-based company said the product is slated for full release by the end of 2016, joining a portfolio of devices that Life Spine launched this year. The spacers allow for the fusion of adjacent segments of spine without removing an existing anterior cervical plate. The locking plate provides security against screw backout, without disturbing the surrounding tissue, according to Life Spine. “Pro-Link Ti offers a low-profile, stand-alone cervical interbody with our groundbreaking Osseo-Loc technology. Osse...
Source: Mass Device - September 20, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Orthopedics Regulatory/Compliance Spinal Life Spine Source Type: news

Sunstar ’s GUIDOR® easy-graft® Alloplastic Bone Grafting System Now Available through Dental Dealers
Bone graft delivers easy handling and can eliminate the need for dental membrane SCHAUMBURG, ILLINOIS, June 10, 2016 — Sunstar Americas announced that it has expanded the purchasing options for its GUIDOR®easy-graft® Alloplastic Bone Grafting System by making it available through a network of 28 authorized U.S. dental dealers.Launched in late 2014 and capable of being syringed directly into a bone defect, GUIDOReasy-graftis the patented1bone grafting material that hardens into a stable, porous scaffold in minutes. Additionally, its ability to harden into a stable, porous scaffold allows clinicians to cho...
Source: Dental Technology Blog - September 20, 2016 Category: Dentistry Source Type: news

Bonesupport touts high infection eradication rate in prospective trial
Bonesupport today released data from the prospective trial of its Cerament G injectable antibiotic-eluting bone substitute, touting a 96% infection eradication rate in patients treated with the substitute. Data from the study was published in The Bone and Joint Journal, the company said. Cerament G is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while preventing colonization of microorganisms by eluting the antibiotic gentamicin. “The results th...
Source: Mass Device - September 1, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Orthopedics Bonesupport Source Type: news

FDA releases July 2016 510(k) clearances
510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL DECISIONS RENDERED DURING THE PERIOD July 2016 TOTAL 510(k)s THIS PERIOD 236 TOTAL WITH SUMMARIES 220 TOTAL WITH STATEMENTS 16 DEVICE: Dakin's Skin and Wound Cleanser CENTURY PHARMACEUTICALS, INC. 510(k) NO: K150208(Traditional) ATTN: Stephen Deardorff PHONE NO : 1 317 8494210 10377 HAGUE RD. SE DECISION MADE: 21-JUL-16 INDIANAPOLIS IN 46256 510(k) SUMMARY AVAILABLE FROM FDA DEVICE: Sheath Introducer BIOTEQUE CORP. 510(k) NO: K150932(Traditional) ATTN: Simon Lin PHONE NO : 886 2 25710269 5 F-6, NO. 2...
Source: Mass Device - August 31, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Return to play following meniscus surgery - Brelin AM, Rue JP.
Meniscus tears are commonly encountered in the athletic population and can result in significant loss of playing time. Current treatment methods for acute tears consist of meniscectomy and meniscal repair, whereas meniscal allograft transplant is reserved ... (Source: SafetyLit)
Source: SafetyLit - August 27, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Amedica wins expanded FDA indication for Valeo II spinal fusion devices
Amedica (NSDQ:AMDA) said yesterday it won expanded FDA clearance for additional sizes of its Valeo II lateral lumbar interbody fusion device. The Valeo II lateral lumbar fusion device is made out of proprietary medical grade silicon nitride ceramic and includes 2nd-generation instrumentation for improved patient safety, the Salt Lake City, Utah-based company said. The device is indicated for intervertebral body fusion of the spine in skeletally mature patients with the use of an autograft to facilitate fusion, the company said. “I’m delighted to announce the recent FDA clearance of our expanded silicon nitride ...
Source: Mass Device - August 26, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Spinal Amedica Source Type: news

Derma Sciences touts Medicare reimbursement win
Derma Sciences (NSDQ:DSCI) said yesterday that Medicare Administrative Contractor National Government Services will now consider the company’s Amnioexcel amniotic allograft membrane for coverage. The change comes as NGS, which serves states in the Northeast and Midwest, sets to retire its local coverage determination for cellular or tissue based products as of September 1st. The change will allow Derma Sciences’ Amnioexcel to be considered with appropriate documentation of medical necessity as a second-line therapy, following standard wound care treatment. “We are very pleased wit...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news

Derma Sciences, Organogenesis tout Medicare reimbursement win
Updated to include more information, commentary from Organogenesis. Medicare administrative contractor National Government Services has retired previous coverage policies on cellular and tissue-based products, effective September 1st. The change will allow new coverages and reimbursement through Medicare for such products based on FDA labeling and packaging. Derma Sciences (NSDQ:DSCI and Organogenesis have said the changes will allow for their products to receive coverage and reimbursement for individuals covered under NGS. Approximately 24 million Medicare Part B beneficiaries are covered by NGS, ...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news

Pregnancy After Kidney Transplant and Allograft Failure Risk Pregnancy After Kidney Transplant and Allograft Failure Risk
Delaying pregnancy after kidney transplantation may decrease the risk of allograft failure. What is the optimal timing?American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Osteovation Bone Graft Cement in Sinus Lift Procedure?
 I was thinking of using Osteovation a calcium phosphate bone cement for the graft.   (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - August 23, 2016 Category: Dentistry Authors: osseonews Tags: Clinical Questions Regenerative Source Type: news

Return to play of rugby players after anterior cruciate ligament reconstruction using hamstring autograft: return to sports and graft failure according to age - Takazawa Y, Ikeda H, Saita Y, Kawasaki T, Ishijima M, Nagayama M, Kaneko H, Kaneko K.
PURPOSE: To assess return to play and the frequencies of graft failure in rugby players after anterior cruciate ligament (ACL) reconstruction using a hamstring autograft augmented with an artificial ligament and to compare outcomes between rugby players ag... (Source: SafetyLit)
Source: SafetyLit - August 20, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Bone graft quality?
I would like input on the bone graft quality. I see a kind of a void above the new bone below the sinus. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - August 17, 2016 Category: Dentistry Authors: osseonews Tags: Clinical Cases Regenerative Source Type: news

MassDevice.com +5 | The top 5 medtech stories for August 12, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Bonesupport wins FDA nod for Cerament G trial Bonesupport said it won an investigational device exemption for the Fortify clinical trial of its next-generation Cerament G injectable antibiotic-eluting bone substitute. Cerament ...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Bonesupport wins FDA nod for Cerament G trial
Bonesupport said it won an investigational device exemption for the Fortify clinical trial of its next-generation Cerament G injectable antibiotic-eluting bone substitute. Cerament G product is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while preventing colonization of microorganisms by eluting the antibiotic gentamicin. Bonesupport said Cerament G, which won CE Mark approval in the European Union back in February 2013, is on the mark...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Orthopedics Regulatory/Compliance Source Type: news

Derma Sciences closes $80m deal for BioD
Derma Sciences (NSDQ:DSCI) said yesterday that it closed its acquisition of regenerative allograft maker BioD in a deal worth up to $78 million, including milestones and earn-outs. Princeton, N.J.-based Derma Sciences said it paid $21.3 million up front in a mix of cash and stock; meeting regulatory milestones could mean another $30 million, and the transaction included $26.5 million in earn-outs pegged to net sales growth. The deal, announced July 28, closed August 5, the company said in a regulatory filing. BioD makes a line of allograft products derived from human placental tissue, includin...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Regenerative Medicine Wound Care BioD Derma Sciences Inc. Source Type: news

Bilirubin contributes to immune suppression after islet transplants
(Cell Transplantation Center of Excellence for Aging and Brain Repair) Stress and injury can cause up to a 70 percent loss of transplanted islet cells within 72 hours after transplantation. Bilirubin, an antioxidant, was used successfully as a supplement to suppress the immune response to allograft islet transplantation and also significantly decrease islet cell death after the cells had been isolated and undergone nutrient deprivation and hypoxic (low oxygen) stress. Bilirubin supplementation could improve outcomes after allograft islet cell transplantation to treat type 1 diabetes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 11, 2016 Category: Biology Source Type: news

Spine Wave launches Velocity expandable lateral spine implant
Spine Wave said today it is launching its Velocity L expandable interbody device and XLR II lateral access system, both of which are designed for lateral surgical approaches for spinal procedures. The expandable device is designed to minimize impaction of large lateral implants into collapsed disk spaces through a slim profile which expands to the desired disc space height, the Shelton, Conn.-based company said. “The Velocity L is the culmination of a multiyear effort to develop an implant that embodies all the characteristics surgeons desire in a lateral expandable interbody device. We believe that th...
Source: Mass Device - August 11, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Spinal Surgical Spine Wave Source Type: news

Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers
These cases highlight the use and efficacy of micronized dehydrated human amnion/chorion membrane allografts in patients with diabetic foot ulcers.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Wright Medical surges on Street-beating Q2
Wright Medical (NSDQ:WMGI) saw shares surge over 10% after releasing 2nd quarter earnings that topped the Street in earnings per share but were off on revenue. The Memphis, Tenn.-based company reported losses of $229.4 million, or $2.23 per share, on sales of $170.7 million for the 3 months ended June 26. That amounts to an over 400% increase in losses while sales grew over 100% compared with the same period in 2015. After adjusting to exclude 1-time items, losses per share were 11¢, half of the 22¢ losses per share The Street expected to see for the quarter. The Street’s revenue expectations of $219.7 mill...
Source: Mass Device - August 3, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wright Medical Group Inc. Source Type: news

BioVentus delays $150m IPO
Orthobiologics maker Bioventus postponed its initial public offering which was slated to raise up to $150 million for the company, according to Renaissance Capital. The company plans to float 8.8 million shares at a price range of between $16 and $18, and plans to list on the NASDAQ Global Market under the ticker “BIOV”. The initial public offering was scheduled to open today, according to Renaissance Capital, and the company has yet to announce a new date. At the midpoint of its proposed range, the company would command a fully diluted market value of $566 million, and proceeds from the round should gener...
Source: Mass Device - July 29, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Orthopedics Regenerative Medicine Bioventus LLC Source Type: news

Human Skin Allograft for Wounds With Exposed Tendon or Bone Human Skin Allograft for Wounds With Exposed Tendon or Bone
Cryopreserved skin allografts may be a safe and effective option for treating wounds with exposed bone or tendon. Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2016 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

Orthofix wins Japanese regulatory win for Phoenix spinal fixation system
Orthofix (NSDQ:OFIX) said today it won regulatory approval from the Japanese Ministry of Health, Labor and Wellfare for its Phoenix minimally invasive spinal fixation system. The Phoenix system allows for the percutaneous placement of pedicle screws designed to provide stabilization and correction for spinal fusion patients suffering from degenerative disc disease and other conditions, the company said. “The Japanese approval and full market launch of the Phoenix MIS fixation system represents an important step towards broadening the availability of our spine fixation products globally by entering the 2nd l...
Source: Mass Device - July 28, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Regulatory/Compliance Spinal Orthofix International Source Type: news

My Participatory Medicine Story: Osteonecrosis / Avascular Necrosis
My name is Alexandra Albin (msaxolotl on Twitter) and I have an orthopedic condition called osteonecrosis or avascular necrosis (AVN). AVN is a painful and debilitating bone disease that typically affects long bones, is caused by a loss of blood supply to the bone, and can lead to bone degeneration and the collapse of joint surfaces. AVN can happen for many reasons. In my case it was the result of medications — steroids —given for a misdiagnosed condition of Multiple Sclerosis (MS) in 1994. That was my third strange neurological episode over several years of what was suspected to be MS, but never confirmed. One...
Source: Society for Participatory Medicine - July 28, 2016 Category: Journals (General) Authors: Mayank Agarwal Tags: Member Updates Newsletter Alexandra Albin AVN CEO of my own body osteonecrosis paralyzed baldder participatory medicine vascular Necrosis Source Type: news

Orthofix touts high fusion rates in Trinity Evolution study
This study demonstrated the effectiveness of Trinity Evolution in achieving a solid fusion when used in this manner, indicating that it is a viable option for patients needing anterior cervical discectomy and fusion,” co-author Dr. Timothy Peppers of Scripps Hospital said in a prepared statement. Orthofix reported significantly improved neck function and neck/arm pain at 6 and 12 months, with no serious adverse events related to the Trinity Evolution. Fusion rates were 78.6% at 6 months and 93.5% after 12 months. “MTF is committed to research to ensure innovative clinical options exist for all patients. We are ...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Regenerative Medicine Spinal Orthofix International Source Type: news

Bioventus sets terms on $150m IPO
Orthobiologics maker Bioventus today released terms for its $150 million initial public offering, looking to float 8.8 million shares at between $16 and $18 per share, with plans to list on the NASDAQ Global Market under the ticker “BIOV”. At the midpoint of its proposed range, the company would command a fully diluted market value of $566 million, and proceeds from the round should generate between $141 and $159 million, according to an SEC filing from the company. The company originally announced plans for the IPO earlier this month, planning to use proceeds from the round to pay off its debt. Durha...
Source: Mass Device - July 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Bioventus LLC Smith & Nephew Source Type: news

Does Osteochondral Allograft Transplant Keep Athletes From Sport?Does Osteochondral Allograft Transplant Keep Athletes From Sport?
Athletes who undergo a transplantation of osteochondral tissue from a cadaver to repair a knee may return to sport at a rate of 76%, a new study suggests. Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - July 12, 2016 Category: Orthopaedics Tags: Orthopaedics News Source Type: news

Saving Knees with Allograft
CHICAGO. (Ivanhoe Newswire) -- More than one-third of all Americans report being affected by knee pain. Knee replacement surgery can offer relief, but the implants only last between 12 and 15 years. Patients under the age of 40 aren’t usually considered good candidates for the procedure because they would need too many revision operations. Now there’s a simple surgery that’s saving knees in younger patients. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - July 11, 2016 Category: Consumer Health News Source Type: news

Osteochondral allograft transplantation effective for treating knee cartilage injuries
For athletes and highly active patients who sustain cartilage injuries to their knee, an osteochondral allograft transplantation can be a successful treatment option, according to new research. The study showed these patients were consistently able to return to sport or recreational activities after the surgery, though frequently at a lower activity level. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 10, 2016 Category: Science Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 1, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Nestle poaches Fresenius CEO Schneider Nestle lured the CEO of Fresenius, Ulf Mark Schneider, to the corner office this week. Fresenius promoted CFO Stephan Sturm to replace Schneider. Read more   4. Biotronik wins...
Source: Mass Device - July 1, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Bioventus files for $150m IPO
Orthobiologics maker Bioventus yesterday registered for an initial public offering it plans to use to pay off debt. Durham, N.C.-based Bioventus was formed in 2012 when Smith & Nephew (NYSE:SNN) spun out its biologics and clinical therapies division in a joint venture with venture capital firm Essex Woodlands. In October 2014 Bioventus acquired the OsteoAMP product line from Advanced Biologics for an undisclosed amount; late last year the company added BioStructures, a developer of absorbable bone grafts, also for an undisclosed amount. In January Bioventus named former Medtronic (NYSE:MDT...
Source: Mass Device - July 1, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Orthopedics Regenerative Medicine Bioventus LLC Source Type: news

Elevated troponin I should not rule out donor hearts
Donor cardiac troponin I level is not associated with intermediate-term mortality, cardiac allograft vasculopathy or primary graft failure in patients receiving heart transplants, US researchers report. (Source: MedWire News)
Source: MedWire News - June 27, 2016 Category: Consumer Health News Tags: Heart failure Source Type: news

Centinel Spine wins Australian clearance for Stalif L implant
Centinel Spine said yesterday it won Australian Therapeutic Goods Administration clearance for its Stalif L no-profile lateral lumbar integrated interbody system. Centinel Spine touts the Stalif L as the only lateral device to offer a no-profile, compressive lag fixation device with proprietary anti-backout technology and 12-degrees of lordosis, as well as a large chamber for bone graft to support fusion. “This clearance expands our International No-Profile, Integrated Interbody market. Stalif has enjoyed a long successful history in Australia and now Stalif L exemplifies our continued commitment to be...
Source: Mass Device - June 24, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Regulatory/Compliance Spinal Centinel Spine LLC Source Type: news

Sunstar’s GUIDOR® easy-graft® Alloplastic Bone Grafting System Now Available through Dental Dealers
Bone graft delivers easy handling and can eliminate the need for dental membrane  SCHAUMBURG, ILLINOIS, June 10, 2016— Sunstar Americas announced that it has expanded the purchasing options for its GUIDOR® easy-graft® Alloplastic Bone Grafting System by making it available through a network of 28 authorized U.S. dental dealers. Launched in late 2014 and capable of being syringed directly into a bone defect, GUIDOR easy-graft is the patented1 bone grafting material that hardens into a stable, porous scaffold in minutes. Additionally, its ability to harden into a stable, porous scaffold allows clinici...
Source: Dental Technology Blog - June 15, 2016 Category: Dentistry Source Type: news

NuVasive picks up neuro monitoring provider Biotronic NeuroNetwork for $98m
NuVasive Inc. (NSDQ:NUVA) said yesterday it bought intraoperative neurophysiological monitoring service provider Biotronic NeuroNetwork for $98 million in cash. Biotronic NeuroNetwork provides neurophysiological monitoring services to surgeons and healthcare facilities in the U.S., as well as remote physician oversight. The company supports more than 45,000 surgeries annually at more than 650 hospitals, NuVasive said. “We are extremely excited about this combination, as it more than doubles NuVasive’s neurophysiology footprint, creating an at-scale services business with improved growth and operational ben...
Source: Mass Device - June 7, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Neurological Patient Monitoring Nuvasive Source Type: news

Intermittent spontaneous cheek swelling after sinus lift: recommendations?
I did a lateral window approach with a sinus lift and bone graft. About 6 weeks post-op, the patient had a large swelling of the cheek overlying the surgical site . (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - May 25, 2016 Category: Dentistry Authors: osseonews Tags: Clinical Questions Regenerative Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 23, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Baxter touts data on Theranova Dialyser efficacy, toxin clearance Baxter today presented data from 24 different abstracts on treatments for end-stage kidney disease, touting 8 that covered its Theranova dialyser, indicated for ...
Source: Mass Device - May 23, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

NuVasive Launches Next Generation Biologics Technology
FDA Cleared Synthetic Bone Graft With Novel Surface Structure That Promotes Bone Formation SAN DIEGO, CA--(Healthcare Sales & Marketing Network) - NuVasive, Inc. (NUVA), a leading medical device company focused on transforming spine surgery with minimal... Devices, Orthopaedic, Neurosurgery, Product LaunchNuVasive, AttraX Putty, synthetic bone graft, spine surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 23, 2016 Category: Pharmaceuticals Source Type: news

Autologous bone grafts: Long-term success from posterior mandible?
The use of particulated autologous retromolar bone grafts is a reliable technique for the horizontal reconstruction of local alveolar ridge deficiencies. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - May 23, 2016 Category: Dentistry Authors: osseonews Tags: Implant News Source Type: news

NuVasive launches Attrax bone putty in the U.S.
NuVasive Inc. (NSDQ:NUVA) said today that it’s launching its Attrax bone putty in the U.S., after winning 510(k) clearance from the FDA in October 2015. The synthetic bone graft putty is designed to encourage bone growth at the site of a spinal fusion procedure. “We are excited to officially launch Attrax putty for surgical use in the U.S. and expect it to be a cornerstone of our expanding biologics portfolio,” president & COO Pat Miles said in prepared remarks. “Attrax Putty has helped improve outcomes for more than 20,000 spine patients worldwide, and we are pleased to now bring this...
Source: Mass Device - May 23, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Orthopedics Regenerative Medicine Spinal Nuvasive Source Type: news

I Favor Allograft Replacement for Menisci Torn Beyond RepairI Favor Allograft Replacement for Menisci Torn Beyond Repair
Whether a meniscus transplant can prevent arthritis is not yet known, but, says a noted surgeon, the procedure does appear to offer the best hope for cartilage protection in these patients. Medscape Orthopedics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2016 Category: Consumer Health News Tags: Orthopaedics Article Source Type: news

Halifax Man Receives First Penis Transplant In U.S. At Mass General
BOSTON (CBS) – A man from Halifax has become the first person to receive a penis transplant in the United States, Massachusetts General Hospital announced Monday. Thomas Manning, 64, underwent the 15-hour transplant operation, called a genitourinary vascularized composite allograft (GUVCA) transplant, earlier this month. “Our courageous patient, Thomas Manning, continues to do well, and we are optimistic about this outcome and future,” said Dr. Curtis Cetrulo, who helped lead the surgical team along with Dr. Dicken Ko, at a press conference Monday morning. Cetrulo said that due to penile cancer most ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 16, 2016 Category: Consumer Health News Authors: miketoole Tags: Health Local News Syndicated Local Halifax Massachusetts General Hospital penis transplant Thomas Manning Source Type: news

Liver Transplant Allograft Dysfunction and Kidney FunctionLiver Transplant Allograft Dysfunction and Kidney Function
Early allograft dysfunction after liver transplantation may lead to renal dysfunction in the form of acute kidney injury or end-stage renal disease. American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2016 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Tag Team Takes on Tricky Back Trouble
NEW YORK CITY. (Ivanhoe Newswire) -- Every year, hundreds of thousands of Americans have back surgery and for a growing number of patients, the operations require fusing bone, or bone grafts, and a large amount of hardware. With complex spine surgery comes a higher risk of complications, but a new approach may be fixing backs and saving lives. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - May 3, 2016 Category: Consumer Health News Source Type: news

Amniotic Membrane Allograft for Chronic Diabetic Foot UlcersAmniotic Membrane Allograft for Chronic Diabetic Foot Ulcers
Is dehydrated amniotic membrane allograft safe and effective in the management of chronic diabetic foot ulcers? Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 28, 2016 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

Amniox Medical touts reimbursement wins, extended cryo lifespan
Amniox Medical this month touted a reimbursement win from Palmetto Medicare as well as a 2-year cryopreserved lifespan for its Neox Cord 1k as it attempts to position itself as a market leader in wound care. The Atlanta, Ga.-based company said that Palmetto Medicare recently included Amniox’s Neox Cord 1k and Neox 100 would allografts in a new skin substitute reimbursement policy, growing the product reach to more than 70% of Medicare patients. The policy shift will allow for skin substitute applications that are medically necessary and follow proper billing guidelines, the company said. “We now have coverage f...
Source: Mass Device - April 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Regenerative Medicine Amniox Medical Source Type: news

Bone-graft venture Artoss hunts for $1.8M
Bone-grafting venture Artoss Inc. is seeking $1.8 million in financing a little more than a year after its technology received U.S. regulatory approval. Led by executives who helped spearhead ApaTech's Actifuse bone-graft product line, Artross has already raised $365,000 from angel investors. ApaTech was sold to the former Baxter International Inc. six years ago in a deal worth up to $330 million (Baxter has since split into two companies). Bone grafts are used to replace and repair bone. Some… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 20, 2016 Category: Pharmaceuticals Authors: Katharine Grayson Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 20, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Earnings Roundup: Intuitive Surgical, Abbott & St. Jude post street-beating Q1s Its earnings season again, with major players Intuitive Surgical, Abbott and St. Jude Medical all reporting 1st quarters that beat the street. ...
Source: Mass Device - April 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Bone Biologics closes $5.8m round
Regenerative orthobiologic company Bone Biologics said it recently closed a $5.75 million round joined by the Musculoskeletal Transplant Foundation, Orthofix (NSDQ:OFIX) and Hankey Capital to support development of its bone graft substitute. Boston-based Bone Biologics is developing Nell-1, a bone growth factor designed to be an alternative to other bone growth factors used in surgical procedures such as spinal fusions. “We are pleased with the completion of this round of funding in a challenging investment environment which will allow the company to further execute on its development strategy. The confiden...
Source: Mass Device - April 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Regenerative Medicine Spinal Bone Biologics Corp. Source Type: news

How I Chose My Surgeon
Note: Ever since a college soccer injury almost 40 years ago, I've had serious issues with my knee. This is the first in a three-part series that talks about my own very recent knee surgery--from the process of choosing the best possible surgeon through my recovery and return to a more active life -- Dr. Kevin Stone As an orthopedic surgeon, picking another orthopedic surgeon to operate on your own knee is tricky. It was tough enough when my wife insisted that I operate on her knee. She rightly felt that no one else would care about her as much as I did. And since I had invented the procedures to replace her arthritic kne...
Source: Healthy Living - The Huffington Post - April 15, 2016 Category: Consumer Health News Source Type: news

Senator calls on Medtronic, FDA for bone graft injury data
(Reuters) - U.S. Senator Al Franken asked federal regulators and Medtronic Inc for detailed information about injuries associated with the company's bone graft Infuse following a newspaper report that Medtronic hid thousands of adverse events linked to the product. (Source: Reuters: Health)
Source: Reuters: Health - April 13, 2016 Category: Consumer Health News Tags: healthNews Source Type: news